Adding Alkaline Water (WTER) to 2022 Beverage Watch List at $0.46, More Names Coming.
The Alkaline Water Company (WTER). Identifies $15 Million in Cost Savings and Margin Enhancements.
With nearly $200 million in sales over the last five years,...
What is NAC (N-Acetyl-L-Cysteine)? (Dr Eric Berg)
https://youtu.be/oPdGOrqTfhA
What is NAC good for? (and How Much to Take?)
What is NAC good for?
NAC or N-Acetyl-Cysteine is good for the following:
It helps produce the antioxidant Glutathione...
Chula Vista Scamster Gets Pinched
Great detective work by the SEC on this. If you ever wonder how/why your stock or stock you're following drops from $1.00 to $0.10...
Revive Therapeutics (RVVTF) Enters the Danger Zone.
What Danger You Ask?
Danger #1, the FDA doesn't like the data, and you own the stock.
Danger #2, the FDA does like the data, and...
Adding Provention Bio (PRVB) $4.60 to 2022 Biotech Watch List.
This is in our 'Stocks we Hope to Double' Watch List.
LIVE QUOTE
Provention Bio (PRVB) Updates.
RELATED: Revive Therapeutics (RVVTF) Enters the Danger Zone.
Provention Bio...
AI and Machine Learning Start-Up Nowigence (NWGO) Announces Deal With EquiPPP Technologies (NSE: EQIPPP).
Nowigence CEO Anoop Bhatia was voted most innovative AI NLP Company CEO 2020.With over two decades in various GE companies across different countries –...
Bill Hwang Had $20 Billion, Then Lost It All in Two Days (Bloomberg).
With all the news on leveraged Bitcoin blowups being reported, let's not forget leverage can blowup an Equity portfolio too. Forgotten in under a...
Provention (PRVB) Price Target $18.
Headline Says Downgrade, But That's Near 300% Higher From Here!
LIVE QUOTE
Provention Bio (NASDAQ:PRVB) PT Lowered to $18.00 (MarketBeat).
July 7th: Provention Bio (NASDAQ:PRVB - Get Rating) had its...
Smart for Life (SMFL) Capitulates?
We Are Long Term Bullish on Smart for Life. After a Volatile Post IPO Trading, we may Have Seen the Bottom.
When we say...
Althira (ATHA) $2.50, is Latest Alzheimer’s Trial Victim. Down 70%
Nearly 100 Alzheimer’s programs have failed in the past decade.
Biotech investors should study or at least become familiar with the trials that fail to...